Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?

Enrollment in metastatic breast cancer trials usually requires measurable lesions, but patients with invasive lobular carcinoma (ILC) tend to form diffuse disease. We found that the proportion of patients with metastatic ILC enrolled in clinical trials at our institution was significantly lower than...

Descripción completa

Detalles Bibliográficos
Autores principales: Abel, Mary Kathryn, Melisko, Michelle E., Rugo, Hope S., Chien, A. Jo, Diaz, Italia, Levine, Julia K., Griffin, Ann, McGuire, Joseph, Esserman, Laura J., Borno, Hala T., Mukhtar, Rita A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547221/
https://www.ncbi.nlm.nih.gov/pubmed/34697300
http://dx.doi.org/10.1038/s41523-021-00348-z
Descripción
Sumario:Enrollment in metastatic breast cancer trials usually requires measurable lesions, but patients with invasive lobular carcinoma (ILC) tend to form diffuse disease. We found that the proportion of patients with metastatic ILC enrolled in clinical trials at our institution was significantly lower than that of patients with invasive ductal carcinoma (IDC). Possible links between requiring measurable disease and decreased enrollment of ILC patients require further study to ensure equitable trial access.

Ejemplares similares